Category Archives: C diff Global Community Support Program

The C Diff Foundation Offers Patients, Family Members, and Clinicians Global Community Support

We are pleased to announce the

C. diff. Global Community Support Program —   an extension of  our

existing patient program – C. diff. Nationwide Community Support Program.

Our Foundation Members and Medical Advocates, leading the support groups, via: teleconferencing, will now have the ability to offer support to patients, families, clinicians, and individuals seeking support —  in  the U.S. and 57 countries.

Below you will find the list of countries, with their local cities,  able
to participate in our teleconferencing support groups:

Argentina – Buenos Aires and Cordoba
Australia – Adelaide, Brisbane, Melbourne, Perth, Sydney
Austria – Countrywide, Vienna
Bahrain – Countrywide
Belgium – Brussels
Brazil – Belo Horizonte, Curitiba, Rio de Janeiro, Sao Paulo
Bulgaria – Sofia
Canada – Calgary, Edmonton, Halifax, Hamilton, Montreal, Ottawa, Quebec City, Toronto,
Vancouver, Winnipeg.
Chile – Santiago
China – Beijing
Columbia – Bogota
Costa Rica – National VolP
Croatia – Zagreb
Cyprus – Nicosia
Czech Republic – Prague
Denmark – Countrywide
Dominican Republic – Santo Domingo
El Salvador – San Salvador
Finland – Helsinki
France – Marseille, Paris
Germany – Berlin, Frankfurt, Hamburg, Munich
Greece – Athens
Hong Kong – Countrywide
Hungary – Budapest
India – Bangalore, Delhi, Mumbai
Ireland – Dublin, National VolP
Israel – Jerusalem, Tel Aviv
Italy – Milan, Rome
Japan – Tokyo
Latvia- Riga
Lithuania – Vilnius
Luxembourg – Countrywide
Malaysia – Kuala Lumpur
Malta – Countrywide
Mexico – Guadalajara, Mexico City, Monterrey
Netherlands – Amsterdam
New Zealand – Auckland
Norway – Oslo
Panama – Panama City
Peru – Lima
Poland – Warsaw
Portugal – Countrywide
Puerto Rico – Aguadilla
Romania – Bucharest
Russia – Moscow
Singapore – Singapore
Slovakia – Bratislava
Slovenia – Ljubljana
South Africa – Cape Town, Johannesburg
South Korea – Seoul
Spain – Barcelona, Madrid
Sweden – Malmo, Stockholm
Switzerland – Bern, Geneva, Zurich
Turkey – Istanbul
Ukraine – National VolP
United Kingdom – Birmingham, Edinburgh, Leeds, Liverpool, London, Manchester, National.
Venezuela – Caracas

Registration will remain the same – through the main number (919) 201-1512
or utilizing the nationwide U.S. Hot-Line 1-844-FOR-CDIF, or from the Foundation website
http://www.cdifffoundation.org C. diff. Global Community Support page.

Support is only a phone call away worldwide

CdiffGlobalSupportF

Season’s Greetings From the C Diff Foundation

 

 

CdiffHolidayFront 001
There is no time more fitting to say thank you and Season’s Greetings from all of us at
The C Diff Foundation and to wish you a Happy Holiday Season.

 

 

Special wishes are being sent out  to the many patients and families who have witnessed or have been diagnosed with a C. difficile infection;  May you have a New Year of restored health, support, hope, and renewed happiness.

Warm wishes,
The C Diff Foundation Members

C Diff Foundation Board of Directors:

Nancy C Caralla, Scott Battles, Dr. Ahmed A. M. Al Mandalawi, MD,
Tiffani M. Eberflus, Rowaland R. Dory, Angelo Ortiz

Mental Health Advisory Committee
Lesa Bridges, LCSW, MSW, Chairperson

Research and Development Committee
Dr. Martha R. Clokie, MS, PhD
Dr. Simon Cutting, MS,PhD, Chairperson
Dr. David Cook, MS, PhD
Dr. Rahma Wehelie, PhD
Dr. Hudson Garrett, Jr., PhD, MSN, MPH, FNP, CSRN, VA-BC, CDONA,FACONA,DON-CLTC™, C-NAC™, PLNC

Medical Advisory Board:
Dr. Mark Wilcox, MD, Chairperson
Dr. Rosie Lyles, MD
Dr. Sadeq A. Quraishi, MD

C. diff. Nationwide Community Support Program:
Dr. Paul Feuerstadt, MD, Medical Advocate
Dr. Caterina Oneto, MD, Medical Advocate
Lisa Hurka-Covington – MD Support Leader
Scott Battles – MO Support Leader
Karen Factor, RD- FL Support Leader
Roy Poole, CO Support Leader

Pediatric Support, Research and Development Committee
Tiffani Eberflus, LPN, Chairperson

C Diff  Volunteer Advocate Program
Angelo Ortiz, Chairperson

Marketing and Graphic Arts Committee
Anthony DelMonaco, Marketing VP
Joel Davis, BS, Chairperson

Nutrition Wellness
Karen Factor, RD, MS, Chairperson

Biologic Research and Development Committee 
Michael Kaleko, MD, PhD, Senior Vice President, Reseaerch & Development Synthetic Biologics
Joseph Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs, Synthetic Biolgics
Andy Bristol, PhD, Vice President, Research & Development, Synthetic Biologics

 

C Diff Foundation Welcomes Dr. Caterina Oneto, MD

oneto_for_the_web

 

We are pleased to welcome Dr. Caterina Oneto, MD to the
C Diff Foundation. 

Dr. Oneto presides as a Medical Advocate for the  
C. diff. Nationwide Community Support Program teleconferencing sessions.

 

Cdiff2015CDNCSPostCard

 

Dr. Caterina Oneto is a Clinical Assistant Professor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine. 

Fluent in Spanish, she graduated with a degree in Medicine and Surgery from the
Universidad de Valparaiso in Chile. She completed her residency in
Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. 

With expertise in endoscopy, colonoscopy, capsule endoscopy, liver and pancreatic diseases, Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridium Difficile and FMT (Fecal Microbiota Transplantation). 

C Diff Foundation Welcomes Dr. Paul Feuerstadt, MD, FACG

drPaulfeuerstadt

 

We are pleased to welcome Dr. Paul Feuerstadt, MD to the
C Diff Foundation.  Dr. Feuerstadt presides as Medical Advocate
for the C. diff. Nationwide Community Support Program.

 

A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.

Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on Clostridium difficile infection. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts and textbook chapters. Another passion of Dr. Feuerstadt’s is teaching, frequently mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as a Clinical Instructor of Medicine. His clinical practice is his ultimate passion filling the majority of his work time seeing a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the
St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden and Milford, Connecticut.

C. difficile Infection (CDI) C Diff Foundation Opens a New Avenue – C. diff. Nationwide Community Support Program

CdiffForRelease-1

The C Diff Foundation introduces the  C. diff. Nationwide Community Support (CDNCS) program beginning in November  for patients, families, survivors and for anyone seeking information and support.

C. difficile (C. diff.) infections caused almost half a million infections among patients in the United States in a single year, according to a 2015 study by the Centers for Disease Control and Prevention (CDC).

In addition, an estimated 15,000 deaths are directly attributable to C. difficile infections, making them a substantial cause of infectious disease death in the United States. [i].

As of 2015, there is an absence of professional C. diff. (CDI) support groups in America. The          C Diff Foundation has pioneered a collaborative plan and developed support groups in a variety of availability and locations to meet the needs of individuals seeking C. diff. information and support.

“We found it to be of the utmost importance to implement this new pathway for support and healing after speaking with numerous patients, family members, and fellow-C. diff. survivors,”

We now speak for the thousands of patients within the United States who, each year, are diagnosed with a C. diff. infection. This growth, in part, reflects the value C. diff. support groups will provide, not only to patients, their spouses, and families who are living with and recovering from a C. diff. infection, but also to the countless number of individuals who will become more aware of a C. diff. infection, the importance of early detection, appropriate treatments, and environmental safety protocols. There will also be Bereavement support group sessions for   C. diff. survivors mourning the loss of loved ones following their death from C. diff. infection involvement.

Beginning November 2015 the CDNCS groups will be available to all individuals via: Teleconferencing with some groups advancing and adding computer application programs in 2016. CDNCS groups will provide support and information  to 15 participants in each session.

The CDNCS program sessions will be hosted via: Teleconferencing with leaders hosting from Maryland, Florida, Missouri, Colorado, Ohio, and Oregon.

The Colorado CDNCS group is offered at a public venue and will be hosted in Arvada, Colo. every third Tuesday of each month, beginning November 17th. The Meeting will start at 5:30 p.m. and end at 7 p.m lead by a C Diff Foundation Volunteer Advocate and C. diff. survivor          Mr. Roy Poole.

To participate in any CDNCS group being offered during each month, all interested participants will be asked to register through the Nationwide Hot-Line (1-844-FOR-CDIF) or through the   website https://cdifffoundation.org/ where registered individuals will receive a reply e-mail containing support group access information.

  • The Support Registration Page  will be available on November 1st.

The C. diff. Nationwide Community Support group leaders will provide a menu of topics being shared each month on the C Diff Foundation’s website ranging from Financial Crisis Relief, Bereavement, Nutrition, Mental Health, to C. diff. infection updates and everyday life during and after being treated for a prolonged illness. Teleconference sessions will also host healthcare professional topic experts

There is evidence that people who attend support group meetings have a better understanding of the illness and their treatment choices. They also tend to experience less anxiety, develop a more positive outlook, and a better ability to cope and adapt to life during and after the treatment for C. diff.

There is a Purpose:

A diagnosis of a C. diff. infection is unexpected and almost always traumatic. As a result, it is not uncommon for newly diagnosed patients to experience a wide range of emotions including, confusion, bewilderment, anger, fear, panic, and denial. Many people find that just having an opportunity to talk with another person, who has experienced the same situation, to help alleviate some of the anxiety and distress they commonly experience.

Individuals also find that they benefit not only from the support they receive, but also from the sense of well-being they gain from helping others. It has been said “support is not something you do for others but rather something you do with others.”

“None of us can do this alone – all of us can do this together.”

 

Follow the C Diff Foundation on Twitter @cdiffFoundation #cdiff2015 and                                        Facebook https://www.facebook.com/CdiffFoundationRadio.

Note/citation: [i] http://www.cdc.gov/drugresistance/biggest_threats.html